This session offers a comprehensive overview of the latest evidence and clinical perspectives on anabolic therapy across diverse patient populations.
Prof. Yasuhiro Takeuch presents the clinical value and efficacy of the 'anabolic-first strategy' based on real-world clinical data.
Prof. Namki Hong introduces the effects of anabolic agents in premenopausal women with low bone mass.
Prof. Seung Shin Park will discuss the evidence for anabolic therapy in rare bone diseases and future research and treatment directions.
Together, these presentations aim to provide clinicians with valuable insights to optimize anabolic treatment strategies effectively.

Symposium 7 will discuss major advances in rare bone disease, providing clinically relevant updates from leading experts.
Prof. Adalbert Raimann will present current and upcoming approaches in XLH care, with a particular focus on the role of burosumab.
Prof. Nobuaki Ito will provide an in-depth review of acquired osteomalacia driven by autoantibodies against PHEX, highlighting its mechanisms and diagnostic considerations. Prof. Yumie Rhee will discuss the evolving spectrum of parathyroid neoplasia, ranging from atypical tumors to carcinoma. This session will deliver meaningful insights for rare bone disorders.

This session highlights the dynamic interplay between three key metabolic tissues: bone, muscle, and fat. Renowned experts will discuss the lifelong mechanical and biochemical coupling of the bone-muscle unit, the emerging impact of novel anti-obesity medications on muscle health, and the complex "friend-or-foe" relationship between adipocytes and myocytes. This session offers essential updates on sarcopenia, obesity, and osteosarcopenia for clinicians and researchers.